On the basis of these prior findings, that KRAS-variant patients respond to cetuximab in combination with radiation and cisplatin with improved outcomes, but with increased radiosensitivity at baseline (15), and prior work indicating that the KRAS-variant is found frequently in patients with NSCLC (10), we tested patients from RTOG 0617 for the KRAS-variant to investigate the outcomes for this genetic subgroup of patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.